Precigen stock jumped nearly 18% in pre-open trading after the company released first-quarter 2026 results that materially exceeded Wall Street expectations. Total revenue for the quarter climbed to $23.3 million, up from $1.3 million in the same period last year, with $21.6 million attributable to PAPZIMEOS sales.
The PAPZIMEOS contribution surpassed both the company’s own guidance floor of more than $18 million and the consensus estimate of roughly $20.8 million. Management highlighted the rapid commercial uptake of the product and the resulting revenue ramp as central drivers of the quarter’s outperformance.
Profitability metrics showed improvement, with a net loss narrowing to $7.9 million, or $0.02 per share, compared with a net loss of $54.2 million, or $0.18 per share, in the prior-year quarter.
On the company earnings call, CEO Helen Sabzevari emphasized the strength of the launch and the path forward for PAPZIMEOS, stating: "We are thrilled with the strength of the PAPZIMEOS launch and the pace of revenue growth as we drive broad commercial success across the US and work toward expanded market opportunities in additional geographies and the pediatric patient population."
Analyst reactions and commercial metrics
The results prompted at least two analyst target increases. Citizens raised its price target on PGEN to $11 from $9 while maintaining a Market Outperform rating. H.C. Wainwright lifted its target to $11 from $10 while keeping a Buy rating. Those revisions followed the clearer-than-expected revenue trajectory stemming from PAPZIMEOS.
Management also disclosed several commercial and reimbursement milestones in support of ongoing sales momentum: PAPZIMEOS currently has roughly 400 hub-enrolled patients; payer coverage extends to approximately 297 million U.S. lives; a permanent J-code took effect on April 1, 2026; and a marketing application with the European Medicines Agency (EMA) is under review. CFO Harry Thomasian Jr. added: "In the second quarter of 2026, we are seeing continued strength in revenue growth from PAPZIMEOS."
Market context and trading behavior
The broader market backdrop was constructive for growth-oriented biotechnology names on the day of the release, with the NASDAQ rising and the S&P 500 also posting gains. Nevertheless, sector peers showed mixed and mostly modest moves, indicating that the pre-market surge in PGEN was primarily stock-specific rather than the result of a wider sector rally.
Investors will also note recent insider activity: insiders sold $15.8 million worth of shares in the prior three months with no reported insider buying. That selling is a separate datapoint that market participants may weigh against the company’s fundamental improvements.
Management outlook and valuation context
Company management expressed confidence in the commercial trajectory and reiterated expectations to reach cash flow breakeven by the end of 2026 without the need to tap capital markets. The combination of the decisive earnings beat, a rapid revenue ramp from PAPZIMEOS, management’s cash flow guidance, and the analyst target increases produced one of the sharpest pre-market moves in the stock in recent memory, driving the share price toward its 52-week high of $5.465.
Takeaway
Precigen’s first-quarter 2026 performance was driven overwhelmingly by PAPZIMEOS, which delivered a transformational revenue uplift and prompted positive analyst reactions. While market reaction was strong, investors may weigh the company’s operational momentum against insider selling and the remaining regulatory review process in Europe.